FDA allows Houston cancer doctor to resume drug trial

Por um escritor misterioso

Last updated 07 julho 2024

FDA allows Houston cancer doctor to resume drug trial

Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - The Lancet Oncology

Katy Rezvani MD Anderson Cancer Center

Gene Editing for Cancer Is Coming of Age, Article

At the Bedside: Pancreatic cancer patient 'back on track' after UTHealth Houston clinical trial therapy shrinks tumor - UTHealth Houston

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study - The Lancet Oncology

Funda Meric-Bernstam MD Anderson Cancer Center

UTHealth Houston

Doctor claims to cure pediatric cancer, critics skeptical

At the Bedside: Pancreatic cancer patient 'back on track' after UTHealth Houston clinical trial therapy shrinks tumor - UTHealth Houston

FDA panel: Benefit of 'highly anticipated' lung cancer drug can't be interpreted reliably

At the Bedside: New focal therapies at UTHealth Houston make prostate cancer treatment easier on patients - UTHealth News - UTHealth Houston

FibroGen limited access to Duchenne muscular dystrophy drug after failed clinical trial. But mom says it works for her son. - San Francisco Business Times

Ashish M. Kamat MD Anderson Cancer Center

FDA agrees to let patients get controversial drug

Novartis challenges Pfizer with strong breast cancer drug data

Recomendado para você